On the glycolytic side, Yang and colleagues demonstrated that inhibition of ACSS2 in ovarian cancer impairs acetate metabolism and glycolysis, leading to the activation of nuclear SIRT1 (209). Here, SIRT1 is linked to ovarian carcinoma.